Evidence map›Paper›PMID 41471227›Full record

ReviewPathogens (Basel, Switzerland)2025

Preclinical Models of Oropouche Virus Infection and Disease.

Daniel Morley, Emma Kennedy, Stuart Dowall

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniel MorleyUK Health Security Agency, Porton Down, Wiltshire SP4 0JG, UK.ORCID 0009-0002-8335-0155
Emma KennedyUK Health Security Agency, Porton Down, Wiltshire SP4 0JG, UK.ORCID 0000-0002-3632-6163
Stuart DowallUK Health Security Agency, Porton Down, Wiltshire SP4 0JG, UK.

Funding

Department of Health and Social Care N/A
6 · The paper itself

Abstract

Oropouche virus (OROV) is an emerging and underreported arbovirus with dengue-like symptoms confounding diagnosis. OROV is also neuroinvasive, with a small number of cases presenting severe neurological symptoms. There have been recently reported deaths from confirmed cases of OROV and reported instances of vertical transmission from mother to foetus, with confirmed cases in Brazil and a congenital anomaly, reportedly as a consequence of OROV infection in Cuba, with further cases under investigation. Whilst cases of OROV infection occur mainly in South America, many cases have been imported elsewhere, including the United States and Europe. Despite the emerging threat to public health, animal modelling to study OROV pathogenicity and immunity and to evaluate therapeutic candidates remains limited. For this review, we carried out a literature search through major research databases (PubMed and Scopus) up to September 2025 to capture the extent of in vivo model development for this pathogen. We identified only 17 relevant primary research articles within these criteria which detailed hamster, mouse and non-human primate (NHP) models. Here, we discuss the extent of in vivo model development for OROV. In summary, small and large animal models need to be assessed with recent clinical isolates and reassortants, asymptomatic disease presentation in the NHP model requires further study and the hamster model shows potential for use in pathogenicity and vaccine or antiviral efficacy studies. We also compile relevant metadata and discuss the need for an animal model that more closely resembles human disease.

Indexed as

Bunyaviridae InfectionsDisease Models, AnimalOrthobunyavirusAnimalsCricetinaeHumansMicearbovirushamstermodelmousenon-human primateoropouchepreclinical

Identifiers

PMID41471227
PMCPMC12735927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.